Recruiting

Observational Study

Sponsor:

Cardiology Research UBC

Code:

NCT06103123

Conditions

Myocarditis

Myocarditis Acute

Pericarditis

Pericarditis Acute

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire

Baseline Quality of Life questionnaire

Study Details

Brief summary:

Myocarditis is inflammation of the heart muscle. Pericarditis is inflammation of the lining surrounding the heart muscle. Symptoms of these conditions can include pain in the chest and rapid or irregular heartbeat. There are many different causes for myocarditis and pericarditis including COVID-19 infection.

The MYCOVACC study will identify patients using local screening strategies, including research communications, care provider referrals, and medical record review. The retrospective component of the study will collect information about patients suffering from vaccine associated myopericarditis and COVID-19 associated myopericarditis. Consenting patients will then be prospectively followed according to standard of care protocols. The main objectives of MYCOVACC are to describe the rate of major adverse cardiovascular events, functional outcomes including quality of life, and myocardial recovery through imaging.

Conditions

Myocarditis

Myocarditis Acute

Pericarditis

Pericarditis Acute

Study ID

NCT06103123

Start date

Apr 23, 2023

Status verified date

Oct, 2023

Completion date

Apr 23, 2025

Anticipated

Primary completion date

Mar 23, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Inclusion criteria for vaccine associated myocarditis/pericarditis.

1. COVID-19 vaccination within previous 42 days. AND
2. At least one cardiac symptom of suspected myocarditis/pericarditis (Appendix 5).

OR At least two non-specific symptoms (Appendix 5). OR In infants and young children, at least two non-specific pediatric symptoms (Appendix 5).

OR No symptoms, but abnormal histopathology or a combination of abnormal cardiac biomarkers with abnormal cardiac imaging (echo or MRI).

AND
3. At least one of the following objective findings (Brighton Criteria case definitions, Appendices 1 to 5):

1. Histopathologic examination of myocardial tissue (autopsy or endomyocardial biopsy) showed myocardial inflammation.
2. Elevated myocardial biomarker (Troponin T, Troponin I, or CK-MB).
3. Cardiac MRI abnormality.
4. Echocardiographic abnormality.
5. New or worsening arrhythmia on electrocardiogram, Holter monitor, or telemetry.
6. Elevated inflammation biomarkers: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hs-CRP, or D-Dimer.
7. Physical examination pericardial friction rub or pulsus paradoxus.
8. Pericardial fluid or inflammation by imaging (echo, MRI, or CT).
9. Enlarged heart on chest radiograph.

AND
4. No alternative cause of presentation. e.g. infectious or autoimmune myocarditis.
  • Inclusion criteria for COVID-19 associated myocarditis/pericarditis

1. COVID-19 infection within the previous 42 days.

AND
2. Myocarditis/pericarditis as per Brighton Criteria for vaccine associated myocarditis/pericarditis.

AND
3. No alternative cause of presentation.

Inclusion criteria alternative etiology myocarditis.

1. Myocarditis/pericarditis as per Brighton Criteria for vaccine associated myocarditis/pericarditis.

AND
2. No alternative cause of presentation.

Exclusion Criteria:

  • For prospective invitation and follow-up, inability to provide informed consent. Consent will be sought from patients or their authorised substitute decision maker.
  • Patients not fulfilling Brighton Criteria levels 1-3 will be excluded if they are level 4 (insufficient evidence for myocarditis) or Level 5 (not myocarditis) or have an alternative diagnosis such as myocardial infarction.

Study Design

Enrollment

500 participants

Anticipated

Interventions and Outcome Measures

Arms

mRNA COVID-19 vaccine associated myocarditis

Participants who had developed myocarditis within 42 days of getting a mRNA COVID-19 vaccine

mRNA COVID-19 vaccine associated pericarditis

Participants who had developed pericarditis within 42 days of getting a mRNA COVID-19 vaccine

COVID-19 infection associated myocarditis

Participants who had developed myocarditis within 42 days of being infected with the SARS-COV-2 virus

COVID-19 infection associated pericarditis

Participants who had developed pericarditis within 42 days of being infected with the SARS-COV-2 virus

Alternative etiology myocarditis

Any participants with myocarditis that is not associated with the mRNA COVID-19 vaccine or SARS-COV-2 viral infection

Interventions

Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire

Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives

Baseline Quality of Life questionnaire

Only baseline quality of life questionnaires will be utilized in the alternative etiology myocarditis cohort as they will not be followed up in the study

Primary outcome measure

  • Composite Major Adverse Cardiac Event (MACE) at 30 days post vaccination (preferred by cardiovascular community) and at 42 days post vaccination (preferred by vaccine monitoring investigators) [ Time Frame: From date of vaccination and up to 3 years ]
  • Recovery of cardiac function in patients with previously documented abnormal cardiac function [ Time Frame: Through study completion, an average of 3 years ]
  • Quality of life using validated instruments at baseline, 3 months, 12 months, and annually [ Time Frame: Through study completion, an average of 3 years ]
  • Depression and anxiety using validated instruments at baseline, 3 months, 12 months, and annually [ Time Frame: Through study completion, an average of 3 years ]
  • Physical activity using validated instruments at baseline, 3 months, 12 months, and annually [ Time Frame: Through study completion, an average of 3 years ]

Central Contacts and Locations

Central contacts

Locations

Vancouver General Hospital

Recruiting

Vancouver, British Columbia, Canada, V5Z 1M9

Contacts

Principal Investigator:

Nathaniel Hawkins, MD

More Information

Sponsor

Cardiology Research UBC

Last update posted

Oct 26, 2023

Last verified

Oct, 2023

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Cardiology Research UBC on 2023-10-26.